VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the post-hoc analyses of the ARCHES trial (NCT02677896), which investigated androgen deprivation therapy (ADT) with enzalutamide (ENZA) or a placebo in metastatic hormone-sensitive prostate cancer (mHSPC). The post-hoc analyses assessed how the pattern of metastatic spread impacts the efficacy of ENZA + ADT in mHSPC patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter